Nils Winkelmann1, Max Desole1,2, Inken Hilgendorf1, Thomas Ernst1, Herbert G Sayer1,3, Christa Kunert1, Lars-Olof Mügge1, Andreas Hochhaus1, Sebastian Scholl4. 1. Klinik für Innere Medizin II (Abteilung Hämatologie und Internistische Onkologie), Universitätsklinikum Jena, Am Klinikum 1, 07740, Jena, Germany. 2. HELIOS Klinikum Emil von Behring, Berlin, Germany. 3. HELIOS Klinikum, Erfurt, Germany. 4. Klinik für Innere Medizin II (Abteilung Hämatologie und Internistische Onkologie), Universitätsklinikum Jena, Am Klinikum 1, 07740, Jena, Germany. sebastian.scholl@med.uni-jena.de.
Abstract
INTRODUCTION: Even in the era of proteasome inhibitors and immunomodulatory drugs, the autologous stem cell transplantation after high-dose melphalan continues to represent a standard approach for myeloma patients in first-line therapy. Different mobilization chemotherapies before stem cell apheresis have been published while cyclophosphamide at a dose level of up to 4 g/m2 has been evaluated and is commonly applied. In contrast, lower dose levels of cyclophosphamide (e.g., 1.5 g/m2) did not result in a sufficient collection of stem cells. METHODS: We retrospectively analyzed the impact of "intermediate-dose" (ID-CY, 2.5 g/m2) versus "high-dose" (HD-CY, 4 g/m2) cyclophosphamide in 101 (48 vs. 53) consecutively evaluable myeloma patients (median age 59 years, range 32-72 years) who underwent stem cell mobilization after induction chemotherapy. Successful stem cell harvest was defined as a stem cell yield of at least 5 million CD34 cells per kg bodyweight. Evaluation of toxicity especially considered infectious complications and hematological toxicity in both subgroups. RESULTS: Successful stem cell mobilization was achieved in 40 of 48 (83 %) and 44 of 53 (83 %) patients, respectively. The median time to apheresis (11 vs. 12 days) and the median CD34 content of stem cell harvest (8.3 vs. 7.6 million CD34 cells per kg bodyweight) did not differ significantly between both groups. There was a significant difference of WBC nadir in favor of the cyclophosphamide regimen with 2.5 g/m2 (0.8 vs. 0.3 Gpt/L, p = 0.021), and neutropenic fever was more often observed in patients who received 4 g/m2 cyclophosphamide (34 vs. 15 %, p = 0.078). Importantly, after induction chemotherapy using the VCD regimen (bortezomib, cyclophosphamide, dexamethasone), successful stem cell mobilization was achieved in 26 of 29 (90 %) patients treated with 2.5 g/m2 and 21 of 25 (84 %) patients receiving 4 g/m2 cyclophosphamide, respectively. CONCLUSIONS: ID-CY is safe and highly effective for stem cell mobilization in patients with newly diagnosed myeloma and associated with a reduced toxicity compared to HD-CY.
INTRODUCTION: Even in the era of proteasome inhibitors and immunomodulatory drugs, the autologous stem cell transplantation after high-dose melphalan continues to represent a standard approach for myelomapatients in first-line therapy. Different mobilization chemotherapies before stem cell apheresis have been published while cyclophosphamide at a dose level of up to 4 g/m2 has been evaluated and is commonly applied. In contrast, lower dose levels of cyclophosphamide (e.g., 1.5 g/m2) did not result in a sufficient collection of stem cells. METHODS: We retrospectively analyzed the impact of "intermediate-dose" (ID-CY, 2.5 g/m2) versus "high-dose" (HD-CY, 4 g/m2) cyclophosphamide in 101 (48 vs. 53) consecutively evaluable myelomapatients (median age 59 years, range 32-72 years) who underwent stem cell mobilization after induction chemotherapy. Successful stem cell harvest was defined as a stem cell yield of at least 5 million CD34 cells per kg bodyweight. Evaluation of toxicity especially considered infectious complications and hematological toxicity in both subgroups. RESULTS: Successful stem cell mobilization was achieved in 40 of 48 (83 %) and 44 of 53 (83 %) patients, respectively. The median time to apheresis (11 vs. 12 days) and the median CD34 content of stem cell harvest (8.3 vs. 7.6 million CD34 cells per kg bodyweight) did not differ significantly between both groups. There was a significant difference of WBC nadir in favor of the cyclophosphamide regimen with 2.5 g/m2 (0.8 vs. 0.3 Gpt/L, p = 0.021), and neutropenic fever was more often observed in patients who received 4 g/m2 cyclophosphamide (34 vs. 15 %, p = 0.078). Importantly, after induction chemotherapy using the VCD regimen (bortezomib, cyclophosphamide, dexamethasone), successful stem cell mobilization was achieved in 26 of 29 (90 %) patients treated with 2.5 g/m2 and 21 of 25 (84 %) patients receiving 4 g/m2 cyclophosphamide, respectively. CONCLUSIONS:ID-CY is safe and highly effective for stem cell mobilization in patients with newly diagnosed myeloma and associated with a reduced toxicity compared to HD-CY.
Authors: F Cavallo; S Bringhen; G Milone; D Ben-Yehuda; A Nagler; E Calabrese; N Cascavilla; V Montefusco; B Lupo; A M Liberati; C Crippa; F Rossini; R Passera; F Patriarca; A M Cafro; P Omedè; A M Carella; J Peccatori; L Catalano; T Caravita; P Musto; M T Petrucci; M Boccadoro; A Palumbo Journal: Leukemia Date: 2011-06-03 Impact factor: 11.528
Authors: Evangelos Terpos; Martina Kleber; Monika Engelhardt; Sonja Zweegman; Francesca Gay; Efstathios Kastritis; Niels W C J van de Donk; Benedetto Bruno; Orhan Sezer; Annemiek Broijl; Sara Bringhen; Meral Beksac; Alessandra Larocca; Roman Hajek; Pellegrino Musto; Hans Erik Johnsen; Fortunato Morabito; Heinz Ludwig; Michele Cavo; Hermann Einsele; Pieter Sonneveld; Meletios A Dimopoulos; Antonio Palumbo Journal: Haematologica Date: 2015-10 Impact factor: 9.941
Authors: G Perea; A Sureda; R Martino; A Altés; C Martínez; E Cabezudo; B Amill; G A Martín-Henao; Y González; L Muñoz; M Peyret; S Brunet; J Sierra Journal: Ann Hematol Date: 2001-10 Impact factor: 3.673
Authors: A Sureda; P Bader; S Cesaro; P Dreger; R F Duarte; C Dufour; J H F Falkenburg; D Farge-Bancel; A Gennery; N Kröger; F Lanza; J C Marsh; A Nagler; C Peters; A Velardi; M Mohty; A Madrigal Journal: Bone Marrow Transplant Date: 2015-03-23 Impact factor: 5.483
Authors: F Awan; S T Kochuparambil; D E Falconer; A Cumpston; S Leadmon; K Watkins; D Deremer; A Jillella; M Craig; M Hamadani Journal: Bone Marrow Transplant Date: 2013-04-15 Impact factor: 5.483
Authors: Anand P Jillella; Celalettin Ustun; Eric Robach; Durdu Sertkaya; Cecily DiPiro; Andre M Kallab; Wendy G Brick; Paul M Dainer; Abdullah Kutlar; Andrea R Townsend; Russell E Burgess Journal: J Hematother Stem Cell Res Date: 2003-04
Authors: Martin Kropff; Peter Liebisch; Stefan Knop; Katja Weisel; Hannes Wand; Claudia-Nanette Gann; Wolfgang E Berdel; Herrmann Einsele Journal: Ann Hematol Date: 2009-03-10 Impact factor: 3.673